Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
Astellas to pay Sutro $90 million for ADCs for cold tumors
by Gina Vitale
June 30, 2022
| A version of this story appeared in
Volume 100, Issue 24
Astellas Pharma and the cancer therapy company Sutro Biopharma have formed a partnership to advance immunostimulatory antibody-drug conjugates (ADCs). They aim to use the ADCs to treat cold tumors, which are tumors that are unlikely to bring about a strong immune response. Sutro will get $90 million to develop ADCs for three biological targets and up to $422.5 million in milestones for each. Astellas will be responsible for clinical development.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X